While the virus hasn’t made a sustained leap into humans, vaccines and treatments are being developed ahead of an outbreak.

Influenza Vaccines Market Research Report Influenza Vaccines Market is estimated to valued at USD 8.30 Bn in 2024 and is expected to reach USD 13.43 Bn by 2031, exhibiting CAGR of 7.1% from 2024-2031.

Influenza Vaccines Market is estimated to valued at USD 8.30 Bn in 2024 and is expected to reach USD 13.43 Bn by 2031, exhibiting CAGR of 7.1% from 2024-2031 ...

Influenza Vaccines Market is estimated to valued at USD 8.30 Bn in 2024 and is expected to reach USD 13.43 Bn by 2031, exhibiting CAGR of 7.1% from 2024-2031 BURLINGAME, CA, UNITED STATES, January ...

Depemokimab data reveals 72% reduction in hospitalizations; projected sales hit £4 billion. GSK plc GSK expects strong momentum in the specialty business segment to continue with growth from ...

Following GSK’s deal-heavy end to 2024, Chief Scientific Officer Tony Wood, Ph.D., doesn’t expect the trend to let up in the new year, zeroing in on partnerships that can expand knowledge ...

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

Eli Lilly made a $2.5 billion deal for a breast cancer drug; GSK reached a $1 billion-plus deal for IDRx. The announcements suggest a potential rebound in M&A deals in the healthcare sector for 2025.

GSK has agreed to buy US biopharmaceutical business IDRx in a deal worth up to $1.15billion (£1billion). Under the agreement, GSK will pay $1billion upfront to acquire the Massachusetts-based ...

In a deal worth up to $1.15 billion, GSK is acquiring precision medicine biotech IDRx and its phase 3-ready gastrointestinal cancer asset. “We really became impressed with what IDRx had achieved ...

January 13, 2025--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based ...